Exicure, Inc. Common Stock
XCURStock
$1.62−76.35%52W
Market Cap$11.96M
P/E—
Div yield—
Beta3.77
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-81.62%
Price vs S&P 500 (4W)-25.94%
VGM Score23.18
Market Capitalization$11.96M
Analyst Recommendations
Oct 2022
Nov 2022
Dec 2022
Jan 2023
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
XCURExicure, Inc. Common Stock | C | F | F | $1.62 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Exicure Inc is an early-stage biotechnology company developing nucleic acid therapeutics targeting validated disease pathways. The company specializes in RNA-based therapeutic approaches to address unmet clinical needs.